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Abstract
In this study of the effect of bipolar status and presence of BDNF Val66Met polymorphism on differences in regional brain
volumes, we hypothesized based on previous studies that 1) bipolar subjects will have smaller regional brain volumes than
healthy controls; 2) BDNF Met66 allele carriers within the same population are likely to have smaller regional brain volumes
as compared to Val66 homozygyotes. In our Caucasian sample of 166 bipolar subjects and 64 gender-matched healthy
controls, we found significant decreases in total (p = 0.005) and regional gray matter volumes in bipolar patients compared
to healthy controls, more pronounced in the inferior and posterior parts of the brain, together with a concomitant increase
in total CSF (p = 0.012) particularly in the lateral ventricles (p = 0.023). However, there was no difference in white matter
volumes noted by other studies. Furthermore we did not find significant differences in other brain regions that have been
reported by other authors. Nor did we find a significant effect of BDNF on these measurements.
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Introduction
Bipolar disorder is a significant psychiatric condition that affects
approximately 1–3% of the population [1]. The pathophysiology
of this disease remains poorly understood, though a dysregulation
of the anterior limbic network is thought to be involved.
Neuroimaging research on this disease has focused on regional
differences of specific cortical volumes, for example, attempting to
evaluate network components by quantifying changes in both the
gray and white matter components of the brain [2,3]. Various
neuroanatomical changes have been observed in structural MRI
studies of bipolar patients compared to healthy subjects, most
notably, increased ventricular volumes (total lateral, right lateral
ventricle and third ventricle) [4] with corresponding regional grey
matter reductions in various subcortical structures implicated in
emotional processing, including the anterior cingulate and insula
cortex [5], amygdala [6] and hippocampus [7].
There has been compelling evidence that genetic factors are
important in determining susceptibility to bipolar disorder. A
candidate gene encoding Brain-Derived Neurotrophic Factor
(BDNF) has been implicated in bipolar disorder [8,9] and other
psychiatric conditions. BDNF potentiates release of dopamine in
nucleus accumbens and is a key regulator of the mesolimbic
dopamine pathway via activation of tyrosine kinase receptors,
regulating identification of and response to emotionally salient
environmental stimuli [10]. With regard to the pathogenesis of
bipolar disorder, studies have shown a reduction in serum BDNF
levels during acute manic and depressive episodes with recovery to
levels similar to that of controls following treatment and remission
to euthymic state [11,12,13], as well as decrease in BDNF levels
with age and length of illness [12]. Of particular interest is a single
nucleotide polymorphism (SNP) in chromosome 11p13 in the
BDNF gene, found to exist in no other vertebrate species except
humans [14]. A valine(G) to methionine (A) substitution in the 59
proregion, specifically on nucleotide 196, codon 66, produces the
SNP. This polymorphism appears to confer genetic susceptibility
to a range of psychiatric disorders including anxiety disorders
[15,16] schizophrenia [17] and of particular relevance to this
paper, mood disorders – both unipolar depression, in particular
late life depression [18,19,20], and bipolar disorder [8,21,22]. It
has been associated with the rapid cycling variant of bipolar
disorder [22]. Some studies [8,21] have found that the Val allele is
over transmitted in bipolar disorder, a pattern also found in
schizophrenia, while others [9] have reported no association
between variation at the BDNF Val66Met locus and susceptibility
to bipolar disorder.
In addition to influencing both susceptibility and clinical course
of psychiatric disorders, the BDNF Val66Met polymorphism has
also been found to impact brain morphology [23,24,25]. The
presence of a Met66 substitution in neurons and neurosecretory
cells leads to three trafficking defects: 1) decreased variant BDNF
distribution into neuronal dendrites, 2) decreased variant BDNF
targeting to secretory granules, and 3) subsequent impairment in
regulated secretion [25,26]. When expressed together in the same
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e38469
cell, Met66 allele alters the intracellular trafficking of ‘‘wild type’’
BDNF (Val allele) through the formation of heterodimers that are
less efficiently sorted into the secretory pathway [27], with an
overall effect of decreased secretion of BDNF at the synapse in the
presence of Met66 allele. Given that BDNF plays an important
role in neurogenesis, neuronal protection, cell survival and
synaptogenesis in the brain, it follows that Met66 allele carriers
should have smaller brain volumes – both total and regional – than
Val/Val homozygotes. Numerous studies have demonstrated
regional differences in the brains of individuals carrying BDNF
val66 or met66 alleles, specifically in gray matter of the prefrontal
cortex [27] and hippocampal volumes [27,28,29] in healthy
populations as well as bipolar populations [7,30].
The major focus of structural neuroimaging so far has been to
define regional changes either through region of interest, voxel-
based mapping or density studies. In this study, we utilized
a regional parcellation technique that enabled us to examine
volumetric regions of gray and white matter and cerebrospinal
fluid, identical to what was done in [2] with the inclusion of
additional regions and structures of the brain previously not
analyzed. In addition, the average age of this population was
younger than in previous studies we conducted [2,31,32,33] to
reduce the potential confounding effect of normal aging on brain
volumes, given that neurotrophins, including BDNF, have been
found to play a critical role in normal aging [34].
Hypothesis
On the basis of previous work done by ourselves and others in
psychiatric and healthy populations [2,4,31], we predicted that
bipolar subjects will have smaller regional brain volumes than
healthy controls, in particular inferior frontal gray matter regions,
with a compensatory increase in the volume of ventricular and
non-ventricular cerebrospinal fluid. Within the same study
population, BDNF Met66 allele carriers (controlled for healthy
vs. bipolar status) are likely to have smaller brain volumes as
compared to Val66 homozygotes, in particular that of gray matter
regions of the prefrontal cortex.
Methods
Sample & Clinical Evaluation
Subjects with bipolar disorder were recruited from outpatient
clinics at Duke University Medical Center in Durham, NC.
Comparison subjects were recruited through community adver-
tisements. The study was approved by the Duke University
Health System Institutional Review Board. After complete
description of the study to the subjects, written informed consent
was obtained.
All subjects completed the SCID (Structured Clinical Interview
for DSM-IV) to assess for psychiatric diagnoses. Bipolar subjects
met DSM-IV criteria [35] for Bipolar I disorder. Comparison
subjects did not meet diagnostic criteria for any psychiatric
diagnosis. All subjects had to be 18 years or older to participate.
Exclusion criteria included meeting DSM-IV diagnostic criteria
for another Axis I psychiatric illnesses, a current manic episode,
and active substance abuse or dependence. Subjects who were
acutely manic were excluded as it would be difficult to ensure that
they stayed still in the MRI scanner. Exclusion criteria further
included any neurological illness, evidence of cognitive impair-
ment (as suggested by a score of #23 on the Mini Mental Status
Exam (MMSE) [36] or contraindications to MRI.
Demographic data were gathered through the clinical evalua-
tion, including a list of current medications and self-report of the
number of previous mood episodes. When subjects could not
provide documentation of their medication regimen, it was
confirmed with the prescribing physician. Current depressive
symptoms were assessed using the Center for Epidemiological
Studies – Depression (CES-D) scale [37].
As we had previously found a racial difference in frequency of
the Val66Met polymorphism [18], we restricted this analysis to
Caucasian American subjects only. Demographics of our study
population are presented in Table 1.
Genotyping
Fresh blood samples were obtained from all participants and
DNA extracted and stored according to methods and quality
checks as previously reported [38]. An aliquot of DNA was used
for genotyping of the BDNF Val66Met polymorphism. DNA
samples were placed in 96-well plates together with no-template
controls and four sample duplicates in an asymmetric pattern to
avoid unintended plate-switching. DNA was polymerase chain
reaction-amplified applying a Taqman by-design assay (Applied
Biosystems) that recognized the single nucleotide polymorphism,
which defines the Val66Met polymorphism (rs6265). The samples
were analyzed using an ABI7900 DNA analyzer (Applied
Biosystems) and the genotypes determined with the SDS software
package (Applied Biosystems). Greater than 95% genotyping
efficiency was required before data was submitted for further
analysis.
Magnetic Resonance Imaging (MRI) Acquisition and
Analysis
1.5T MRI acquisition of axial images was performed on
a whole-body system (SIGNA, GE Medical Systems, Milwaukee,
WI) using the standard head (volumetric) radiofrequency coil. The
scanner alignment light was used to adjust the head tilt and
rotation so that the axial plane lights passed across the cantomeatal
line and then sagittal lights were aligned with centre of the nose. A
rapid sagittal localizer scan confirmed the alignment.
An axial dual-echo fast spin-echo acquisition was obtained. The
images were acquired in two separate acquisitions with a 3 mm
gap between sections. The second acquisition was offset by 3 mm
from the first to create contiguous sections. Images were processed
in DUMC’s Neuropsychiatric Imaging Research Laboratory
(NIRL) on SUN workstations. A semi automated method was
used to convert image intensity to segmented tissue types, making
use of the multiple MR contrasts available to identify different
tissue classifications through a ‘‘seeding’’ process, in which
a trained analyst manually selects pixels in each tissue type to be
identified (gray matter, white matter, cerebrospinal fluid, lesions or
background). The seeding protocol identifies the range of signal
intensities that characterize each tissue type.
Subdivision of the cerebrum into component parcellation
regions was performed using the GRID program which was
developed by NIRL. Each scan was re-aligned to a standard
orientation, including making the anterior commissure–posterior
commissure (AC–PC) plane horizontal. Following this, the planes
were defined. First, a mid-sagittal plane was used to divide the
left and right cerebral hemispheres. Then, an axial plane was
created along the AC–PC plane, dividing superior regions from
inferior. Next, coronal planes were created perpendicular to the
axial plane at the anterior and posterior extent of the corpus
callosum. Finally, a third coronal plane was created at the
midpoint between the first two coronal planes, which divided the
brain into anterior and posterior halves in each hemisphere. A
detailed description can be found in our previous study [2].
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Statistical Analysis
Bivariate association between bipolar cases and controls and
continuous variables (e.g. age) were conducted using t-tests, while
their association with categorical variables were conducted using
chi-squared tests. General linear model (GLM) was used to assess
the associations between volumetric variables with bipolar status
and BDNF genotype. These models were adjusted for age, gender,
cerebrum volume and age of onset. These models also included
two and three way interactions of bipolar status, BDNF genotype,
age and sex. As a first step, whole brain grey and white matter
volumes and CSF was evaluated before regional variations were
explored. Similar analysis was conducted for BDNF Val66Met
genotype, i.e. Met66 allele carriers and Val66 homozygotes.
Significance of associations were assessed at alpha = 0.05. All
analyses were conducted using SAS 9.2 statistical software.
Results
Sample Characteristics
A total of 230 subjects were included in this study. 166 had
a diagnosis of bipolar disorder, and 64 were healthy control
subjects. In our study population, 92 subjects were BDNF Met66
allele carriers while the other 138 subjects were Val66 homo-
zygotes. We found no deviation from Hardy-Weinberg equilibri-
um expectations. Due to the small number of Met66 homozygous
individuals, Met66 carriers were grouped together and sub-
sequently compared with Val66 homozygotes. There was no
significant difference in gender between either population (bipolar
vs. controls, and BDNF Met66 carriers vs. Val66 homozygotes) on
univariate analysis, but difference in age of bipolar vs. control
subjects was slightly significant at p = 0.0343. 46 of these subjects
were from an earlier study we conducted [2], 34 of which were
bipolar and the rest (12) were controls. Overall however, this study
used a younger population with mean age 44.4 years for bipolar
and 49.4 years for controls, compared to 60.5 years and
58.1 years respectively in the previous study. All subjects were of
Caucasian race.
Bipolar Status and Brain Volumes
Overall there were significant differences in total cerebrospinal
fluid (CSF) and total grey matter between bipolar subjects and
healthy controls. Differences were found in 38 variables in the first
model associating bipolar status with brain volume. 26 of these
variables had greater volumes in the bipolar population; these
were all CSF variables (Table 2). Specifically, the CSF variables
having a larger volume in bipolar subjects were: total CSF
(including left and right total), total non ventricular CSF (
including total left, total right, anterior half non ventricular CSF
(and including anterior quarter, right anterior half) and 7
parcellated regions), CSF in right and left anterior half (including
left anterior quarter), right ventricular CSF, and total lateral
ventricles (including parcellation regions 6, 8 and 9, lateral
ventricles in right anterior half).
The remaining 12 variables having greater volumes in the
controls (Table 3) were all grey matter regions. These included
total grey matter (including total left and right brain grey matter),
total non lesion grey matter (cerebrum, left brain and right brain),
non lesion grey matter in posterior half (including right posterior
half) and parcellation regions 5, 7 and 15. Mean cerebrum
volumes (and standard deviations) are as follows: bipolar 1163.66
(128.12) ml, healthy controls 1150.22 (120.20) ml. Three other
brain regions – namely total white matter, left and right putamen
are of particular interest to us because they were previously found
to have significantly different volumes in bipolar versus healthy
subjects [2,3,7]; however, they did not reach statistical significance
in this study and are thus not reported here.
BDNF Genotype and Brain Volumes
A second general linear model was run on the same population
to examine brain morphological differences with BDNF Val66Met
genotype as the independent variable, controlling for age, gender,
cerebrum volume and bipolar status. We did not find a significant
volumetric difference in total gray matter or total white matter
between BDNF Val66 homozygotes and Met66 allele carriers.
Three-way interactions of bipolar status, BDNF genotype and
age or sex were all non-significant.
Discussion
Our study examined the effect of the BDNF Val66Met
genotype on regional brain volumes in a cohort of 230 subjects,
of which 166 were diagnosed with bipolar disorder and the rest
(64) were healthy controls. To our knowledge, this is the first study
examining the relationship of both bipolar status and BDNF
Val66Met genotype on differences in regional brain volumes in
a population of bipolar and healthy subjects. It expands our
understanding of the influence of this genetic locus on brain
morphometry, in the presence and absence of psychiatric illness.
Bipolar Status and Brain Volumes
In our study, cerebrospinal fluid (CSF) regions, including total
CSF, regional non ventricular CSF and the volume of lateral
ventricles, in particular the right ventricle were increased in
bipolar subjects compared to controls. One of the most pervasive
neuroanatomical changes associated with bipolar disease is the
enlargement of lateral and third ventricles [4,39], a change similar
Table 1. Group Differences by Bipolar Status and BDNF Val66Met Genotype.
Bipolar Controls Total n P-value
N 166 64 230
Female (%) 110 (66.3) 50 (78.1) 160 (69.6) p = 0.0798
Mean Age(SD)/years 44.36 (13.70) 49.41 (16.77) p = 0.0343
BDNF Genotype Met allele carriers Val homozygotes
N 92 138 230
Female (%) 62 (67.4) 98 (71.0) p = 0.5585
Mean Age (SD)/years 47.55 (14.38) 44.59 (14.94) p = 0.1385
doi:10.1371/journal.pone.0038469.t001
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Table 2. Variables with larger volumes (ml) in bipolar subjects.
Bipolar (n =166) Controls (n =64)
Brain Region Mean SD Mean SD P-value
Total CSF 251.66 85.14 239.79 75.35 0.0121
Left total CSF 114.06 41.43 107.14 34.85 0.0037
Right total CSF 111.94 38.91 106.32 35.40 0.0121
Non-ventricular CSF in anterior half (Sum of regions 1,2,3,4,5,6,7, and 8) 94.56 31.75 88.38 29.36 0.0025
Non-ventricular CSF in anterior quarter (Sum of regions 1,2,3, and 4) 34.65 12.55 31.94 11.88 0.0066
Non-ventricular CSF in right anterior half 49.85 16.22 46.43 14.66 0.0024
CSF in right anterior quarter 18.79 6.53 17.06 5.89 0.0025
CSF in left anterior half 44.70 15.98 41.95 14.97 0.0042
CSF in left anterior quarter 15.86 6.30 14.87 6.18 0.025
Right ventricle 11.66 6.58 10.22 4.69 0.0099
Non-ventricular CSF 227.77 76.55 218.31 69.24 0.0217
Left non-ventricular CSF 101.83 36.82 95.89 31.69 0.0052
Right non-ventricular CSF 100.28 34.88 96.11 32.29 0.0274
Non-ventricular CSF in region 1 2.62 1.33 2.22 1.06 0.0098
Non-ventricular CSF in region 2 16.17 5.70 14.85 5.33 0.0064
Non-ventricular CSF in region 4 13.54 5.38 12.81 5.44 0.0398
Non-ventricular CSF in region 5 9.91 3.47 9.42 2.87 0.0481
Non-ventricular CSF in region 6 21.15 7.42 19.94 6.91 0.0065
Non-ventricular CSF in region 7 9.81 3.54 9.25 2.66 0.0241
Non-ventricular CSF in region 8 19.03 7.35 17.83 6.92 0.0026
Lateral ventricle in region 6 4.02 2.26 3.45 1.80 0.0045
Lateral ventricle in region 8 4.02 2.23 3.62 1.87 0.0308
Lateral ventricle in region 9 0.84 0.45 0.75 0.35 0.038
Lateral ventricle in right anterior half (Sum of regions 1,2,5, and 6) 4.16 2.28 3.59 1.87 0.0048
Total non-ventricular CSF in the cerebrum (Sum of regions 1–16) 201.99 71.23 191.96 63.52 0.0118
Total lateral ventricles (Sum of regions 1–16) 23.92 13.27 21.43 9.97 0.0234
doi:10.1371/journal.pone.0038469.t002
Table 3. Brain regions with larger volumes (ml) in healthy controls.
Bipolar (n =166) Controls (n =64)
Brain Region Mean SD Mean SD P-value
Total gray matter 637.22 91.30 641.14 106.73 0.0051
Left total gray matter 268.34 38.24 268.70 42.78 0.0221
Right total gray matter 270.80 39.49 271.69 45.06 0.0136
Non lesion gray matter 637.16 91.34 641.08 106.74 0.0051
Left non lesion gray matter 268.31 38.26 268.67 42.79 0.0216
Right non lesion gray matter 270.77 39.50 271.66 45.06 0.0136
Non lesion gray matter in region 5 31.98 5.39 32.71 4.91 0.0143
Non lesion gray matter in region 7 30.06 4.87 30.92 4.80 0.0042
Non lesion gray matter in region 15 21.83 6.16 23.73 6.50 0.0038
Non-lesion gray matter in posterior half
(Sum of regions 9,10,11,12,13,14,15 and 16)
309.05 46.04 310.93 56.30 0.0197
Total non-lesion gray matter in the cerebrum 538.94 77.35 540.46 87.36 0.0144
Non-lesion gray matter in right posterior half (Sum of regions 9,10,13, and 14) 150.81 23.54 151.40 30.22 0.002
doi:10.1371/journal.pone.0038469.t003
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to that seen in schizophrenia [40]. This is not unexpected given
the overlap in clinical presentations of schizophrenia and bipolar
disorder, such as the presence of psychotic features and
disinhibition. In these patients, the enlarged ventricles are often
at the expense of reduced gray and white matter volumes.
In line with our expectations, we detected a statistically
significant difference in total and regional gray matter volumes.
Specifically, we observed smaller gray matter volumes in
parcellation regions 5, 7 and 15 in the bipolar subjects,
corresponding to inferior frontal (regions 5 and 7) and inferior
posterior (region 15) areas of the brain. These gray matter changes
are consistent with structural abnormalities in bipolar disorder
reported elsewhere [2,41], suggesting that the postulated anterior
limbic network of prefrontal-striatal-thalamic structures is likely to
be responsible for mood-regulation. Additionally, when taken
together with a previous study of ours [2] that used a population
encompassing this study’s population but with an older mean age
(mean age 60.5 and 58.1 years respectively in bipolar and healthy
subjects, compared to 44.4 and 49.4 years in this study), it suggests
that significant gray matter reductions in bipolar subjects are
already present at a younger age and may be accelerated with
aging.
We did not find an effect of bipolar status on white matter
volumes in our study. The current body of evidence is mixed;
several studies did not find a difference in white matter volumes
similar to ours [2,41], while a recent study on an Asian population
[3] found loss of white matter networks involving frontal and
prefrontal areas in bipolar subjects compared to healthy controls.
BDNF Genotype and Brain Volumes
We did not find any differences in brain regions or specific
structures as might be predicted by other studies [23,30], in
particular, gray matter volume [30] and dorsolateral prefrontal
cortex [23]. A study by [42] reported a global effect of BDNF
Val66Met polymorphism on brain volumes independent of age
and sex, with Val66 homozygotes having significantly larger total
lobar volumes, particularly in temporal and frontal lobe white
matter. However, none of these differences were borne out in our
study, perhaps a result of differences in patient populations, MRI
acquisition and segmentation protocols. While we would have
liked to look at the effect of BDNF Val66Met genotype on
structures such as the amygdala and caudate nucleus previously
reported in other studies [16,24], insufficient numbers prevented
us from doing so.
Limitations of Study
There are several limitations to our study. First, we were unable
to test for a dose-dependent effect of the BDNF Met66 allele on
brain morphology; given the much lower frequency of the
homozygous Met66 genotype, a larger sample would be needed.
Second, as the hypotheses are exploratory, no adjustments were
made for multiple testing. However, the reported number of tests
conducted here is about 36. At alpha = 0.05, Bonferroni adjusted
alpha [43] is 0.05/36= 0.0014. With this adjusted alpha the
significant results presented here will no longer be significant.’’
Finally, though we were able to control for age, gender and
cerebrum volume, several other clinical characteristics of our
sample population could influence volumetric brain matter
changes. An example would be co-morbid conditions such as
substance abuse and anxiety, which although part of our exclusion
criteria, may not be easily picked up by clinicians at the point of
enrollment into the study. More importantly, our study did not
control for the effect of medication – we did not classify patients
based on their medication status (whether they were on mood
stabilizers or other psychiatric medications) and duration of
treatment prior to study enrolment. This is a potential confound-
ing factor, as increases in grey matter density have been found in
lithium-treated bipolar patients [44] and following a 4-week trial of
lithium in healthy volunteers [45]. Thus, the use of medications in
our patient population may obfuscate the relationship between
bipolar status, BDNF genotype and brain volumes.
Conclusion
Overall, our observations of decreased total and regional gray
matter volumes, particularly in inferior and posterior parts of the
brain, together with a concomitant increase in cerebrospinal fluid
in bipolar patients, suggest that these regions may play a role in
both mood and cognitive symptoms of bipolar disorder, a condition
that appears to be increasingly similar to schizophrenia in both
clinical manifestations and neuroanatomical changes. The pres-
ence of a BDNF Met66 or Val66 allele (BDNF Val66Met
polymorphism) does not appear to confer an effect on regional
brain volumes in either healthy or bipolar patients.
Additional studies enabling us to correlate such findings with
subjects’ clinical course of bipolar disorder (age of onset, family
history and severity of both depressive and manic symptoms, etc.)
may shed more light on the impact of disease on volumetric
regional brain changes. It would also be instructive to further split
the study population into four subgroups along both dimensions
(genotype and bipolar status), so as to examine the effect of BDNF
Val66Met genotype on bipolar and healthy subjects separately.
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